Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind,
parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I
or Bipolar II disorder having a major depressive episode.